ReviewRenal failure2025
Advances in noninvasive diagnosis of renal osteodystrophy.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Low-dose CT for assessing microstructural alterations in Renal Osteodystrophy among uremic patients: a retrospective cohort study.American journal of translational research · 2026Article
- "The Renal Trail Reveals Masked Face" - A Unique Case Series.Contemporary clinical dentistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal osteodystrophy (ROD) refers to the histological abnormalities in bone associated with chronic kidney disease (CKD), closely linked to the progression of CKD, increased risk of fractures, cardiovascular events, and mortality. Early diagnosis and comprehensive assessment of ROD are crucial for enhancing the quality of life of CKD patients and reducing mortality rates. However, the diagnosis and evaluation of ROD remain significant challenges. Although tetracycline double-labeling of iliac crest biopsies is considered the gold standard for diagnosis, its invasiveness and limitations in dynamically monitoring continuous changes in bone morphology restrict its routine application. This article evaluates the research progress in noninvasive diagnostic techniques as alternatives to bone biopsy. These techniques encompass established and emerging bone biomarkers, traditional imaging modalities, and nuclear medicine approaches. The focus is on their application in assessing bone turnover and providing direction for future research. Some individual bone biomarkers and combinations of bone biomarkers have demonstrated considerable potential in the diagnosis of ROD. Quantitative analysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.